KR20190016755A - Diet-food composition for inducing satiation comprising L-tryptophan and dietary fiber of chicory and method for preparing diet tablet using the same - Google Patents
Diet-food composition for inducing satiation comprising L-tryptophan and dietary fiber of chicory and method for preparing diet tablet using the same Download PDFInfo
- Publication number
- KR20190016755A KR20190016755A KR1020170101099A KR20170101099A KR20190016755A KR 20190016755 A KR20190016755 A KR 20190016755A KR 1020170101099 A KR1020170101099 A KR 1020170101099A KR 20170101099 A KR20170101099 A KR 20170101099A KR 20190016755 A KR20190016755 A KR 20190016755A
- Authority
- KR
- South Korea
- Prior art keywords
- tryptophan
- diet
- weight
- tablet
- dietary fiber
- Prior art date
Links
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 title claims abstract description 55
- 239000000203 mixture Substances 0.000 title claims abstract description 44
- 241000723343 Cichorium Species 0.000 title claims abstract description 36
- 235000007542 Cichorium intybus Nutrition 0.000 title claims abstract description 36
- 235000013325 dietary fiber Nutrition 0.000 title claims abstract description 35
- 235000005911 diet Nutrition 0.000 title claims abstract description 31
- 230000037213 diet Effects 0.000 title claims abstract description 29
- 229960004799 tryptophan Drugs 0.000 title claims abstract description 29
- 238000000034 method Methods 0.000 title claims description 18
- 230000001939 inductive effect Effects 0.000 title abstract description 5
- 235000019553 satiation Nutrition 0.000 title 1
- 235000013305 food Nutrition 0.000 claims abstract description 26
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 26
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 22
- 239000011248 coating agent Substances 0.000 claims description 20
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 18
- 229920002678 cellulose Polymers 0.000 claims description 17
- 239000001913 cellulose Substances 0.000 claims description 17
- 239000008187 granular material Substances 0.000 claims description 16
- 239000011575 calcium Substances 0.000 claims description 15
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerol Natural products OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 14
- -1 glycerin fatty acid ester Chemical class 0.000 claims description 14
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 14
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 14
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 14
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims description 14
- 238000002156 mixing Methods 0.000 claims description 14
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 13
- 239000000194 fatty acid Substances 0.000 claims description 13
- 229930195729 fatty acid Natural products 0.000 claims description 13
- 235000011187 glycerol Nutrition 0.000 claims description 13
- 235000019359 magnesium stearate Nutrition 0.000 claims description 13
- 238000000576 coating method Methods 0.000 claims description 11
- 239000000314 lubricant Substances 0.000 claims description 11
- 150000003839 salts Chemical class 0.000 claims description 11
- 239000000377 silicon dioxide Substances 0.000 claims description 11
- 235000012239 silicon dioxide Nutrition 0.000 claims description 11
- IFGCUJZIWBUILZ-UHFFFAOYSA-N sodium 2-[[2-[[hydroxy-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyphosphoryl]amino]-4-methylpentanoyl]amino]-3-(1H-indol-3-yl)propanoic acid Chemical compound [Na+].C=1NC2=CC=CC=C2C=1CC(C(O)=O)NC(=O)C(CC(C)C)NP(O)(=O)OC1OC(C)C(O)C(O)C1O IFGCUJZIWBUILZ-UHFFFAOYSA-N 0.000 claims description 11
- 229920002134 Carboxymethyl cellulose Polymers 0.000 claims description 9
- 235000010948 carboxy methyl cellulose Nutrition 0.000 claims description 9
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 8
- 239000008112 carboxymethyl-cellulose Substances 0.000 claims description 8
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 5
- 229910052791 calcium Inorganic materials 0.000 claims description 4
- 239000007916 tablet composition Substances 0.000 claims description 4
- 239000000835 fiber Substances 0.000 claims description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 2
- 239000008101 lactose Substances 0.000 claims description 2
- 235000012054 meals Nutrition 0.000 claims description 2
- 208000008589 Obesity Diseases 0.000 abstract description 19
- 235000020824 obesity Nutrition 0.000 abstract description 19
- 230000000694 effects Effects 0.000 abstract description 18
- 230000036186 satiety Effects 0.000 abstract description 10
- 235000019627 satiety Nutrition 0.000 abstract description 10
- 239000004480 active ingredient Substances 0.000 abstract description 6
- 235000021407 appetite control Nutrition 0.000 abstract description 3
- 230000002195 synergetic effect Effects 0.000 abstract description 3
- 239000003826 tablet Substances 0.000 description 51
- 230000000052 comparative effect Effects 0.000 description 8
- 235000019525 fullness Nutrition 0.000 description 8
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 8
- 230000001737 promoting effect Effects 0.000 description 7
- 230000037406 food intake Effects 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 6
- 241000700159 Rattus Species 0.000 description 5
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 4
- 235000019789 appetite Nutrition 0.000 description 4
- 230000036528 appetite Effects 0.000 description 4
- 230000037396 body weight Effects 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 235000009200 high fat diet Nutrition 0.000 description 4
- 230000006872 improvement Effects 0.000 description 4
- 230000001965 increasing effect Effects 0.000 description 4
- 239000002994 raw material Substances 0.000 description 4
- 229940076279 serotonin Drugs 0.000 description 4
- 230000004580 weight loss Effects 0.000 description 4
- LUEWUZLMQUOBSB-FSKGGBMCSA-N (2s,3s,4s,5s,6r)-2-[(2r,3s,4r,5r,6s)-6-[(2r,3s,4r,5s,6s)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(2r,4r,5s,6r)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-4,5-dihydroxy-2-(hydroxymethyl)oxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@@H](O[C@@H]2[C@H](O[C@@H](OC3[C@H](O[C@@H](O)[C@@H](O)[C@H]3O)CO)[C@@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O LUEWUZLMQUOBSB-FSKGGBMCSA-N 0.000 description 3
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 3
- 229920002581 Glucomannan Polymers 0.000 description 3
- 229920001202 Inulin Polymers 0.000 description 3
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 235000012631 food intake Nutrition 0.000 description 3
- 229940046240 glucomannan Drugs 0.000 description 3
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 description 3
- 229940029339 inulin Drugs 0.000 description 3
- 229960002477 riboflavin Drugs 0.000 description 3
- 235000019786 weight gain Nutrition 0.000 description 3
- 206010019233 Headaches Diseases 0.000 description 2
- 206010029216 Nervousness Diseases 0.000 description 2
- 229930003270 Vitamin B Natural products 0.000 description 2
- 229930003471 Vitamin B2 Natural products 0.000 description 2
- 210000000577 adipose tissue Anatomy 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 235000019658 bitter taste Nutrition 0.000 description 2
- 235000019219 chocolate Nutrition 0.000 description 2
- 230000000378 dietary effect Effects 0.000 description 2
- 235000018823 dietary intake Nutrition 0.000 description 2
- 235000001916 dieting Nutrition 0.000 description 2
- 230000037228 dieting effect Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 239000007884 disintegrant Substances 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 235000013373 food additive Nutrition 0.000 description 2
- 239000002778 food additive Substances 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- 230000014509 gene expression Effects 0.000 description 2
- 231100000869 headache Toxicity 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 210000000936 intestine Anatomy 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- DHHVAGZRUROJKS-UHFFFAOYSA-N phentermine Chemical compound CC(C)(N)CC1=CC=CC=C1 DHHVAGZRUROJKS-UHFFFAOYSA-N 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 235000002639 sodium chloride Nutrition 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- 235000019156 vitamin B Nutrition 0.000 description 2
- 239000011720 vitamin B Substances 0.000 description 2
- 235000019164 vitamin B2 Nutrition 0.000 description 2
- 239000011716 vitamin B2 Substances 0.000 description 2
- 230000004584 weight gain Effects 0.000 description 2
- PHIQHXFUZVPYII-ZCFIWIBFSA-N (R)-carnitine Chemical compound C[N+](C)(C)C[C@H](O)CC([O-])=O PHIQHXFUZVPYII-ZCFIWIBFSA-N 0.000 description 1
- MIDXCONKKJTLDX-UHFFFAOYSA-N 3,5-dimethylcyclopentane-1,2-dione Chemical compound CC1CC(C)C(=O)C1=O MIDXCONKKJTLDX-UHFFFAOYSA-N 0.000 description 1
- NNDHDYDFEDRMGH-CAEIVAEBSA-N Anthranoyllycoctonine Chemical compound C([C@]12CN(C3[C@@]4(O)[C@]5(O)[C@H]6[C@@H](OC)[C@@H]([C@H](C5)OC)C[C@H]6[C@@]3([C@@H]1[C@@H]4OC)[C@@H](OC)CC2)CC)OC(=O)C1=CC=CC=C1N NNDHDYDFEDRMGH-CAEIVAEBSA-N 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 241000186000 Bifidobacterium Species 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 206010013911 Dysgeusia Diseases 0.000 description 1
- 102000009123 Fibrin Human genes 0.000 description 1
- 108010073385 Fibrin Proteins 0.000 description 1
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 206010020710 Hyperphagia Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- UXOXDDUEWZOAIW-UHFFFAOYSA-N Inuline Natural products CCN1CC2(CC(=O)Oc3ccccc3N)CCC(OC)C45C6CC7C(CC(O)(C6C7OC)C(O)(C(OC)C24)C15)OC UXOXDDUEWZOAIW-UHFFFAOYSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 206010027304 Menopausal symptoms Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 229910004298 SiO 2 Inorganic materials 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 208000001871 Tachycardia Diseases 0.000 description 1
- 229930003451 Vitamin B1 Natural products 0.000 description 1
- 229930003779 Vitamin B12 Natural products 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 239000003463 adsorbent Substances 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- VNRZCPPHNPEBFC-UHFFFAOYSA-N anthranoyllycoctonine Natural products CCN1CC2(COC(=O)c3ccccc3N)CCC(OC)C45C2C(OC)C(O)(C14)C6(O)CC(OC)C7CC5(O)C6C7OC VNRZCPPHNPEBFC-UHFFFAOYSA-N 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 239000003613 bile acid Substances 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 235000021152 breakfast Nutrition 0.000 description 1
- 235000019402 calcium peroxide Nutrition 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 235000013736 caramel Nutrition 0.000 description 1
- 229920006184 cellulose methylcellulose Polymers 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- 239000007910 chewable tablet Substances 0.000 description 1
- 230000001587 cholestatic effect Effects 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 239000011247 coating layer Substances 0.000 description 1
- AGVAZMGAQJOSFJ-WZHZPDAFSA-M cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].N#[C-].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O AGVAZMGAQJOSFJ-WZHZPDAFSA-M 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000013872 defecation Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- JAUGGEIKQIHSMF-UHFFFAOYSA-N dialuminum;dimagnesium;dioxido(oxo)silane;oxygen(2-);hydrate Chemical compound O.[O-2].[O-2].[Mg+2].[Mg+2].[Al+3].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O.[O-][Si]([O-])=O JAUGGEIKQIHSMF-UHFFFAOYSA-N 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 235000005686 eating Nutrition 0.000 description 1
- 235000006694 eating habits Nutrition 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000037149 energy metabolism Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 229950003499 fibrin Drugs 0.000 description 1
- 239000002657 fibrous material Substances 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 235000011194 food seasoning agent Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 235000013376 functional food Nutrition 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 239000008240 homogeneous mixture Substances 0.000 description 1
- 235000012907 honey Nutrition 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 230000009610 hypersensitivity Effects 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- 239000008274 jelly Substances 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000002075 main ingredient Substances 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 230000013011 mating Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
- 229960001252 methamphetamine Drugs 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 230000001151 other effect Effects 0.000 description 1
- 235000020830 overeating Nutrition 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 230000008533 pain sensitivity Effects 0.000 description 1
- 235000019629 palatability Nutrition 0.000 description 1
- 230000002572 peristaltic effect Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 229960003562 phentermine Drugs 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000002250 progressing effect Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 description 1
- 238000007670 refining Methods 0.000 description 1
- 235000019192 riboflavin Nutrition 0.000 description 1
- 239000002151 riboflavin Substances 0.000 description 1
- 230000001624 sedative effect Effects 0.000 description 1
- 238000007493 shaping process Methods 0.000 description 1
- 229960004425 sibutramine Drugs 0.000 description 1
- UNAANXDKBXWMLN-UHFFFAOYSA-N sibutramine Chemical compound C=1C=C(Cl)C=CC=1C1(C(N(C)C)CC(C)C)CCC1 UNAANXDKBXWMLN-UHFFFAOYSA-N 0.000 description 1
- 208000019116 sleep disease Diseases 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 230000006794 tachycardia Effects 0.000 description 1
- 235000019640 taste Nutrition 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229960003495 thiamine Drugs 0.000 description 1
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 235000010374 vitamin B1 Nutrition 0.000 description 1
- 239000011691 vitamin B1 Substances 0.000 description 1
- 235000019163 vitamin B12 Nutrition 0.000 description 1
- 239000011715 vitamin B12 Substances 0.000 description 1
- 235000019158 vitamin B6 Nutrition 0.000 description 1
- 239000011726 vitamin B6 Substances 0.000 description 1
- 229940011671 vitamin b6 Drugs 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/20—Reducing nutritive value; Dietetic products with reduced nutritive value
- A23L33/21—Addition of substantially indigestible substances, e.g. dietary fibres
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/175—Amino acids
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23P—SHAPING OR WORKING OF FOODSTUFFS, NOT FULLY COVERED BY A SINGLE OTHER SUBCLASS
- A23P10/00—Shaping or working of foodstuffs characterised by the products
- A23P10/20—Agglomerating; Granulating; Tabletting
- A23P10/28—Tabletting; Making food bars by compression of a dry powdered mixture
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/332—Promoters of weight control and weight loss
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/02—Acid
- A23V2250/06—Amino acid
- A23V2250/065—Tryptophan
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/20—Natural extracts
- A23V2250/21—Plant extracts
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Mycology (AREA)
- Health & Medical Sciences (AREA)
- Nutrition Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
Description
본 발명은 L-트립토판 및 치커리 식이섬유를 유효성분으로 포함하여 포만감 증진 기능을 갖는 다이어트용 식품 조성물과 이를 이용하여 다이어트용 정제를 제조하는 방법에 관한 것이다.The present invention relates to a food composition for diet having a satiety-improving function comprising L-tryptophan and chicory dietary fiber as an active ingredient, and a method for preparing dietary tablets using the same.
근래 식생활의 서구화, 인스턴트(instant)화 등으로 인해 열량의 섭취는 늘어난 반면 섬유소의 섭취 감소와 운동량의 저하로 인해 비만 또는 각종 성인병의 발병이 증가하고 있으며, 비만은 체내 지방의 과다축적으로 인해 정상적 생리기능에 장애를 주고 당뇨병, 심혈관계 질환, 지질대사 이상, 암 등의 여러 가지 만성적 질환의 원인이 되는 것으로 알려진 바 있어 이와 같은 비만, 성인병의 예방, 개선 및 치료를 위한 방법에 대한 연구가 활발히 진행되고 있다.Recently, the intake of calories has increased due to westernization and instantaneous dietary habits. However, obesity or various diseases have been increasing due to decrease in the amount of fibrin consumption and decrease of exercise, and obesity is caused by excessive accumulation of body fat It is known that it interferes with physiological function and causes various chronic diseases such as diabetes, cardiovascular disease, lipid metabolism abnormality, cancer, etc. Therefore, researches on methods for prevention, improvement and treatment of such obesity and adult diseases actively It is progressing.
종래에는 시부트라민(sibutramine), 펜터민(phentermine), 메탐페타민(methamphetamin) 등과 같은 비만치료제를 이용하여 비만을 개선하기 위한 시도가 있었으나, 상기 비만치료제는 불면증, 신경불안, 두통, 빈맥, 혈압상승, 위장 장애, 과민증, 담즙분비 장애, 지용성 비타민 흡수억제 등의 심각한 부작용이 동반되는 것으로 알려져 이와 같은 문제점을 개선할 수 있는 방법에 다양한 연구가 진행되고 있으며, 최근에는 음식의 섭취를 조절하는 메커니즘을 이해하여 인체 내로 유입되는 칼로리를 차단하고, 체내의 지방을 소비시킴으로써, 체중감량을 유도하기 위한 연구 또한 함께 진행되고 있다.Conventionally, there has been an attempt to improve obesity by using an obesity treatment agent such as sibutramine, phentermine, methamphetamine, etc. However, the above-mentioned obesity treatment agent has insomnia, nervous anxiety, headache, tachycardia, It has been known that there are serious side effects such as disorders, hypersensitivity, cholestatic disorder, and fat-soluble vitamin absorption inhibition. Various studies have been carried out to improve these problems. In recent years, understanding the mechanism of controlling food intake Research is also under way to induce weight loss by blocking calories entering the body and consuming body fat.
한편, 세로토닌은 체내 행복호르몬으로 알려진 신경전달물질로서, 식욕조절에 관련이 있어 체내 세로토닌의 양이 감소하게 되면 우울증이 야기될 수 있고, 이로 인해 식욕이 증가되어 과도한 음식 섭취를 유도해 체중을 증가시킬 수 있으며, 특히, 세로토닌의 원료가 되는 L-트립토판은 필수 아미노산으로서 식품 첨가물로 사용되며, L-트립토판의 혈중 농도와 비만 간의 연관성에 대한 연구에서 L-트립토판의 섭취가 비만인의 체중 조절 및 감소에 효과가 있다는 것이 인체적용시험을 통해 확인된 바 있다.On the other hand, serotonin is a neurotransmitter known as a happy hormone in the body. It is related to appetite control. As the amount of serotonin in the body decreases, depression can be caused. As a result, the appetite is increased to induce excessive food intake L-tryptophan, which is a raw material of serotonin, is used as a food additive as an essential amino acid. In a study on the relationship between the concentration of L-tryptophan and the obesity, the intake of L- The results of the human body test have confirmed that there is an effect on the human body.
하지만, L-트립토판의 경우 아미노산 특유의 쓴 맛으로 인해 섭취가 불편하며 젤리, 츄어블정, 음료 등 맛에 대한 기호가 강한 제품의 경우 기능성과 기호성을 함께 충족할 수 있는 제품 개발이 필요하나 현재 국내에서 판매되는 트립토판을 주 기능원료로 하는 다이어트 제품은 찾아보기 힘들고, 이를 활용한 일부 제품의 경우에도 함유량이 매우 낮아, 이를 이용하여 비만을 효과적으로 개선할 수 있는 방법에 대한 연구가 필요하다.However, in the case of L-tryptophan, it is inconvenient to ingest due to the bitter taste characteristic of amino acids. In the case of products with strong taste for jelly, chewable tablets and beverages, it is necessary to develop a product capable of satisfying functionality and palatability. It is difficult to find a diet product containing tryptophan as a main functional raw material. Also, some of the products using this product are very low in content, and studies on a method of effectively improving obesity using the tryptophan are needed.
본 발명은 상기한 바와 같은 종래기술의 문제점을 해결하기 위해 안출된 것으로, 트립토판 및 치커리 식이섬유를 주원료로하여 포만감 증진 및 배변 촉진 효능의 시너지 효과를 유도하여 우수한 비만 개선 효능을 갖는 다이어트용 식품 조성물 및 이를 이용하여 다이어트용 정제를 제조하는 방법에 관한 기술 내용을 제공하고자 하는 것이다.DISCLOSURE Technical Problem The present invention has been conceived to solve the problems of the prior art as described above, and it is an object of the present invention to provide a food composition for diets having excellent obesity improving effect by inducing synergy of promoting fullness and defecation promotion effect using tryptophan and chicory dietary fiber as main ingredients And a method for producing a tablet for diet using the same.
본 발명의 해결과제는 이상에서 언급한 것들에 한정되지 않으며, 언급되지 아니한 다른 해결과제들은 아래의 기재로부터 당업자에게 명확하게 이해될 수 있을 것이다.The present invention has been made in view of the above problems, and it is an object of the present invention to provide an apparatus and method for controlling the same.
상기한 바와 같은 기술적 과제를 달성하기 위해서 본 발명은, 치커리 식이섬유 및 L-트립토판을 포함하는 다이어트용 식품 조성물을 제공한다.In order to accomplish the above object, the present invention provides a food composition for diet comprising chicory dietary fiber and L-tryptophan.
또한, 상기 다이어트용 식품 조성물은 결정 셀룰로오스, 칼슘 카르복시메틸 셀룰로오즈(CMC-Ca salt), 스테아린산 마그네슘, 하이드록시프로필 메틸 셀룰로오스, 글리세린 지방산에스테르 및 주정을 추가로 포함할 수 있다.In addition, the food composition for diet may further include crystalline cellulose, CMC-Ca salt, magnesium stearate, hydroxypropyl methylcellulose, glycerin fatty acid ester, and alcohol.
또한, 상기 다이어트용 식품 조성물은 35 내지 45 중량%의 치커리 식이섬유, 15 내지 25 중량%의 L-트립토판, 35 내지 40중량%의 결정 셀룰로오스, 1 내지 5 중량%의 카르복시메틸 셀룰로오즈(CMC-Ca salt), 0.1 내지 2 중량%의 스테아린산 마그네슘, 0.1 내지 1 중량%의 하이드록시프로필 메틸 셀룰로오스, 0.1 내지 1 중량%의 글리세린 지방산에스테르 및 0.1 내지 1 중량%의 주정을 포함할 수 있다.Also, the food composition for diet includes 35 to 45 wt% of chicory dietary fiber, 15 to 25 wt% of L-tryptophan, 35 to 40 wt% of crystalline cellulose, 1 to 5 wt% of carboxymethyl cellulose (CMC-Ca 0.1 to 2% by weight of magnesium stearate, 0.1 to 1% by weight of hydroxypropylmethylcellulose, 0.1 to 1% by weight of glycerin fatty acid ester and 0.1 to 1% by weight of a spirit.
또한, 상기 다이어트용 식품 조성물은 정제(tablet) 제형일 수 있으며, 상기 정제는 100 내지 150 mg의 L-트립토판 및 200 내지 300 mg의 치커리 식이섬유를 포함하는 것이 바람직하다.In addition, the food composition for diet may be a tablet formulation, and the tablet preferably contains 100 to 150 mg of L-tryptophan and 200 to 300 mg of chicory dietary fiber.
또한, 본 발명은, (a) 치커리 식이섬유, L-트립토판, 결정셀룰로오스, 칼슘 카르복시메틸 셀룰로오즈(CMC-Ca salt), 이산화규소 및 주정을 포함하는 혼합물을 과립화하여 과립을 제조하는 단계; (b) 상기 과립 및 활택제를 혼합하고 타정하여 나정(naked tablet)을 제조하는 단계; 및 (c) 상기 나정의 표면에 코팅제를 코팅하여 정제(tablet)를 제조하는 단계를 포함하는 다이어트용 정제의 제조방법을 제공한다.(A) granulating a mixture comprising chicory dietary fiber, L-tryptophan, crystalline cellulose, CMC-Ca salt, silicon dioxide and alcohol to produce granules; (b) mixing and granulating the granules and the glidant to form an naked tablet; And (c) coating the surface of the tablet with a coating agent to prepare tablets.
또한, 상기 활택제는 스테아린산마그네슘을 포함하고, 상기 코팅제는 하이드록시프로필 메틸 셀룰로오스, 글리세린 지방산에스테르 및 주정을 포함할 수 있다.In addition, the lubricant may include magnesium stearate, and the coating agent may include hydroxypropyl methylcellulose, glycerin fatty acid ester, and alcohol.
본 발명에 따른 다이어트용 식품 조성물은, L-트립토판과 치커리 식이섬유를 유효성분으로 포함하여, 심리적 및 육체적 포만감 증진을 통한 식욕조절과 배변 촉진 효능의 시너지 효과를 유도하여 우수한 비만 개선 효능을 가지며, 특히, 상기 조성물로 제조된 정제는 섭취가 간편하여 L-트립토판이 갖는 섭취의 불편함을 개선하고 식전 또는 식후에 섭취하면 장시간 동안 충분한 포만감을 공급하여 음식의 섭취량을 줄일 수 있음에 따라 다이어트를 위한 용도로 손쉽게 활용이 가능하다.The food composition for diet according to the present invention contains L-tryptophan and chicory dietary fiber as an active ingredient to induce a synergistic effect of controlling appetite and promoting bowel movement through promotion of psychological and physical fullness, Particularly, the tablets prepared by the above composition are easy to ingest and improve the inconvenience of intake of L-tryptophan, and when they are consumed before or after the meal, they can provide sufficient fullness for a long time to reduce the intake of food, It is easy to use for applications.
본 발명의 효과는 이상에서 언급된 것들에 한정되지 않으며, 언급되지 아니한 다른 효과들은 아래의 기재로부터 당업자에게 명확하게 이해될 수 있을 것이다.The effects of the present invention are not limited to those mentioned above, and other effects not mentioned can be clearly understood by those skilled in the art from the following description.
도 1은 본 발명에 따른 다이어트용 정제의 제조방법을 나타낸 공정도이다.BRIEF DESCRIPTION OF THE DRAWINGS FIG. 1 is a process drawing showing a method for producing a tablet for diet according to the present invention. FIG.
본 발명의 추가적인 목적들, 특징들 및 장점들은 다음의 상세한 설명 및 첨부 도면으로부터 보다 명료하게 이해될 수 있다.Further objects, features and advantages of the present invention will become more apparent from the following detailed description and the accompanying drawings.
본 발명의 상세한 설명에 앞서, 본 발명은 다양한 변경을 도모할 수 있고, 여러 가지 실시예를 가질 수 있는바, 아래에서 설명되고 도면에 도시된 예시들은 본 발명을 특정한 실시 형태에 대해 한정하려는 것이 아니며, 본 발명의 사상 및 기술 범위에 포함되는 모든 변경, 균등물 내지 대체물을 포함하는 것으로 이해되어야 한다.Before describing the present invention in detail, it is to be understood that the present invention is capable of various modifications and various embodiments, and the examples described below and illustrated in the drawings are intended to limit the invention to specific embodiments It is to be understood that the invention includes all modifications, equivalents, and alternatives falling within the spirit and scope of the invention.
어떤 구성요소가 다른 구성요소에 "연결되어" 있다거나 "접속되어" 있다고 언급된 때에는, 그 다른 구성요소에 직접적으로 연결되어 있거나 또는 접속되어 있을 수도 있지만, 중간에 다른 구성요소가 존재할 수도 있다고 이해되어야 할 것이다. 반면에, 어떤 구성요소가 다른 구성요소에 "직접 연결되어" 있다거나 "직접 접속되어" 있다고 언급된 때에는, 중간에 다른 구성요소가 존재하지 않는 것으로 이해되어야 할 것이다.It is to be understood that when an element is referred to as being "connected" or "connected" to another element, it may be directly connected or connected to the other element, . On the other hand, when an element is referred to as being "directly connected" or "directly connected" to another element, it should be understood that there are no other elements in between.
본 명세서에서 사용한 용어는 단지 특정한 실시예를 설명하기 위해 사용된 것으로, 본 발명을 한정하려는 의도는 아니다. 단수의 표현은 문맥상 명백하게 다르게 뜻하지 않는 한, 복수의 표현을 포함한다. 본 명세서에서, "포함하다" 또는 "가지다" 등의 용어는 명세서상에 기재된 특징, 숫자, 단계, 동작, 구성요소, 부품 또는 이들을 조합한 것이 존재함을 지정하려는 것이지, 하나 또는 그 이상의 다른 특징들이나 숫자, 단계, 동작, 구성요소, 부품 또는 이들을 조합한 것들의 존재 또는 부가 가능성을 미리 배제하지 않는 것으로 이해되어야 한다.The terminology used herein is for the purpose of describing particular embodiments only and is not intended to be limiting of the invention. The singular expressions include plural expressions unless the context clearly dictates otherwise. In this specification, the terms "comprises" or "having" and the like refer to the presence of stated features, integers, steps, operations, elements, components, or combinations thereof, But do not preclude the presence or addition of one or more other features, integers, steps, operations, elements, components, or combinations thereof.
또한, 첨부 도면을 참조하여 설명함에 있어, 도면 부호에 관계없이 동일한 구성 요소는 동일한 참조부호를 부여하고 이에 대한 중복되는 설명은 생략하기로 한다. 본 발명을 설명함에 있어서 관련된 공지 기술에 대한 구체적인 설명이 본 발명의 요지를 불필요하게 흐릴 수 있다고 판단되는 경우 그 상세한 설명을 생략한다.In the following description of the present invention with reference to the accompanying drawings, the same components are denoted by the same reference numerals regardless of the reference numerals, and redundant explanations thereof will be omitted. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS Hereinafter, exemplary embodiments of the present invention will be described in detail with reference to the accompanying drawings. In the following description, well-known functions or constructions are not described in detail since they would obscure the invention in unnecessary detail.
이하, 본 발명을 상세히 설명하도록 한다.Hereinafter, the present invention will be described in detail.
본 발명은 본 발명은, 치커리 식이섬유 및 L-트립토판을 포함하는 다이어트용 식품 조성물을 제공한다.The present invention provides a food composition for diet comprising chicory dietary fiber and L-tryptophan.
상기 L-트립토판은 자연적인 수면을 유도하고, 통증 민감성을 저하시키고 긴장, 초조함, 우울증 두통 등을 개선하는 진정 효과와 면역 증진 및 노화방지 효과 등을 나타내며, 콜레스테롤, 혈압조절, 갱년기 증상 개선, 알츠하이머 개선 등의 효능이 있을 뿐만 아니라, 특히, 세로토닌의 원료가 되어 식욕억제, 포만감 증진, 에너지 대사에 관여하며, 비만인의 체중을 감소시키는 효과가 있다.The L-tryptophan exhibits a sedative effect, immune enhancement and anti-aging effect, which induces natural sleeping, reduces pain sensitivity, and improves tension, nervousness, depression headache, etc. It is also effective in controlling cholesterol, blood pressure, improving menopausal symptoms, Not only has an effect of improving the body weight of obesity, but also has an effect of reducing appetite, promoting a feeling of fullness, participating in energy metabolism, and reducing body weight of obesity, especially as a raw material of serotonin.
상기 치커리(chicory) 식이섬유는 천연 식이섬유 소재로서, 올리고 화이버(oligo fiber)라고 불리우는 이눌린(inulin)과 올리고프룩토오스(oligofructose)가 함유되어 있어 포만감 증진을 통한 과식 방지로 비만 예방에 도움을 준다. 또한, 변의 양을 늘리고 비피도 박테리아 등과 같은 장내 유익균의 성장을 자극시켜 배변활동 원활 및 체중 감소 효과가 있으며, 특히, inuline은 저 칼로리 다당류로 혈당 조절을 도와 천연 인슐린으로서의 역할을 하여 혈당 상승을 완화시킴으로써 포만감을 유지시킬 수 있다. The chicory dietary fiber is a natural dietary fiber material that contains inulin and oligofructose called oligo fibers to help prevent overeating by promoting fullness. give. In addition, by increasing the amount of stool and stimulating the growth of beneficial bacteria in the intestines such as Bifidobacterium, it facilitates bowel movement and weight loss. Especially, inuline is a low caloric polysaccharide which helps blood glucose control by acting as a natural insulin, Satisfaction can be maintained by giving.
상기 치커리 식이섬유는 치커리 잎, 줄기, 뿌리 등의 부위에서 추출한 것을 사용할 수 있으나, 바람직하게는, 치커리 뿌리에서 추출하여 이눌린의 함량이 높은 천연물 수용성 식이섬유를 사용할 수 있으며, 이와 같은 치커리의 수용성 식이섬유는 장의 연동운동을 정상화시키고, 대장의 기능을 개선하고 소장 내에서 담즙산과 지질과 결합되어 배출되므로 혈청 콜레스테롤과 중성지방(triglyceride)의 수준을 감소시키는 역할을 할 수 있다.The chicory dietary fiber may be extracted from chicory leaves, stems, roots and the like. Preferably, the chicory dietary fiber may be extracted from chicory roots and used with natural inulin-soluble dietary fiber having a high content of inulin. Fiber can normalize the peristaltic movement of the intestines, improve the function of the large intestine, and release it in combination with bile acids and lipids in the small intestine, thus reducing the levels of serum cholesterol and triglyceride.
또한, 본 발명에 따른 다이어트용 식품 조성물은 식품으로 허용이 가능한 부형제, 결합제, 붕해제, 활택제, 감미제 등을 추가로 혼합하여 식품으로 제조할 수 있으며, 결정셀룰로오스(crystalline cellulose), 칼슘 카르복시메틸셀룰로오즈(calcium carboxymethylcellulose, CMC-Ca salt), 스테아린산 마그네슘(magnesium stearate), 이산화규소(SiO2), 유당, 옥수수전분, 만니톨(mannitol), 메타규산알루민산마그네슘(magnesium aluminometasilicate) 등을 대표적인 예로 들 수 있다. 바람직하게는, 본 발명에 따른 다이어트용 식품 조성물은 결정 셀룰로오스, 칼슘 카르복시메틸 셀룰로오즈(CMC-Ca salt), 스테아린산 마그네슘, 하이드록시프로필 메틸 셀룰로오스, 글리세린 지방산에스테르 및 주정을 추가로 포함할 수 있다.In addition, the food composition for diet according to the present invention can be prepared into foods by further mixing excipients, binders, disintegrants, lubricants, sweeteners, etc., which are acceptable as foods, and include crystalline cellulose, Representative examples include calcium carboxymethylcellulose (CMC-Ca salt), magnesium stearate, silicon dioxide (SiO 2 ), lactose, corn starch, mannitol and magnesium aluminometasilicate have. Preferably, the food composition for diet according to the present invention may further comprise crystalline cellulose, CMC-Ca salt, magnesium stearate, hydroxypropyl methylcellulose, glycerin fatty acid ester and alcohol.
구체적으로, 상기 결정 셀룰로오스는 위장관에서 팽윤, 팽창하여 포만감을 유도하고, 유효성분이 체내 흡수되기 위한 과정 촉진하는 붕해제의 역할을 할 수 있으며, 식품 제조시 혼합물의 유동성을 증진시키고, L-트립토판 및 치커리 식이섬유의 혼합성을 촉진하여 균일한 혼합물을 제조하는 역할을 할 수 있다.Specifically, the crystalline cellulose may serve as a disintegrant which swells and expands in the gastrointestinal tract to induce a satiety feeling, and promotes the process for the absorption of the active ingredient into the body. The crystalline cellulose may improve the fluidity of the mixture during the production of food, It can play a role of promoting the mixing of the chicory dietary fiber and producing a homogeneous mixture.
상기 칼슘 카르복시메틸 셀룰로오스는 유효성분이 체내 흡수되기 위한 과정 촉진하는 정제의 붕해제 역할을 할 수 있으며, 상기 이산화규소는 흡착제로의 역할을 하고, 상기 스테아린산마그네슘은 활택제의 역할을 하고, 정제 제조 과정 중 압축에 의해 발생되는 정제의 몰드 부착을 방지하고, 정제가 정제기에서 배출되는 동안 마찰을 감소시켜 정제에 광택을 부여하는 역할을 한다.The calcium carboxymethyl cellulose may serve as a disintegrating tablet for promoting the absorption of the active ingredient into the body, the silicon dioxide serving as an adsorbent, the magnesium stearate serving as a lubricant, To prevent mold adhesion of the tablets generated by compression, and to reduce the friction while the tablets are discharged from the tablet machine, thereby imparting gloss to the tablets.
상기 하이드록시프로필 메틸 셀룰로오스(Hydroxypropyl-methylcellulose)는 제형의 안전성을 부여하고, 목넘김 부담 최소화시키는 역할을 하며, 제제로부터 약물방출을 제어하기 위한 제어방출 첨가제로 포함될 수 있다.Hydroxypropyl-methylcellulose may be included as a controlled-release additive for controlling the drug release from the preparation, while providing safety of the formulation and minimizing the burden of necking.
상기 글리세린 지방산에스테르는 과건조에 의한 수분 부족을 방지할 수 있으며, 주정은 코팅 부형제로 사용할 수 있다.The glycerin fatty acid esters can prevent the lack of moisture due to overdrying, and can be used as a coating agent for alcohol.
본 발명에 따른 다이어트용 식품 조성물은 식품으로 허용 가능한 올리고당, 꿀, 시럽, 초콜릿 등과 같은 감미료, 소금 등과 같은 기타 시즈닝 재료, 형제, 결합제, 붕해제, 활택제, 교미제, 착향제, 멀티비타민 분말, 착색제 또는 이들의 혼합물을 식품 첨가제로 혼합할 수 있고, 건조분말, 과립제, 캡슐제, 정제, 환제, 음료, 유상액 형태, 다이어트바, 초콜릿, 카라멜 제형, 시리얼 및 과자류 등으로 제형화하여 건강기능식품, 일반식품 등으로 제조되어 사용할 수 있다.The food composition for diets according to the present invention can be used as a food, which can be used as a food, such as sweeteners such as oligosaccharide, honey, syrup, chocolate and the like, other seasoning materials such as salt and the like, siblings, binders, disintegrators, lubricants, mating agents, A coloring agent or a mixture thereof may be mixed with a food additive and formulated into a dry powder, a granule, a capsule, a tablet, a pill, a drink, an emulsion, a diet bar, a chocolate, a caramel, a cereal, Functional food, general food, and the like.
바람직하게는, 상기 다이어트용 식품 조성물은 정제(tablet) 제형으로 제조하는 것이 바람직하고, 이와 같은 정제 제형으로 제조할 경우, L-트립토판 특유의 쓴 맛으로 인한 섭취의 불편감을 해소할 수 있다.Preferably, the food composition for diet is preferably prepared in a tablet formulation, and when prepared in such a tablet formulation, the discomfort of ingestion due to the bitter taste peculiar to L-tryptophan can be solved.
또한, 상기 다이어트용 식품 조성물을 타정기를 이용해 타정하여 정제 제형으로 제조할 경우, 상기 정제는 600 내지 750 mg의 총중량을 가지며, 100 내지 150 mg의 L-트립토판 및 200 내지 300 mg의 치커리 식이섬유를 함유하도록 구성하고 1일 2회 섭취가능하도록 하여 일일 동안 필요한 L-트립토판 및 치커리 식이섬유의 최적 공급량으로 체내 도입할 수 있으며, 이로 인한 포만감 증진효과를 통해 우수한 비만개선 효과를 유도할 수 있다.In addition, when the food composition for diet is prepared by tableting using a tablet machine, the tablets have a total weight of 600 to 750 mg, 100 to 150 mg of L-tryptophan and 200 to 300 mg of chicory dietary fiber And can be taken twice a day, so that it can be introduced into the body at an optimum supply amount of L-tryptophan and chicory dietary fiber required for a day, and it is possible to induce an excellent obesity improvement effect through the fullness-enhancing effect.
일례로, 본 발명에 따른 다이어트용 식품 조성물은 35 내지 45 중량%의 치커리 식이섬유, 15 내지 25 중량%의 L-트립토판, 35 내지 40중량%의 결정 셀룰로오스, 1 내지 5 중량%의 카르복시메틸 셀룰로오즈(CMC-Ca salt), 1 내지 5 중량%의 이산화규소, 0.1 내지 2 중량%의 스테아린산 마그네슘, 0.1 내지 1 중량%의 하이드록시프로필 메틸 셀룰로오스, 0.1 내지 1 중량%의 글리세린 지방산에스테르 및 0.1 내지 1 중량%의 주정을 포함하여 다이어트용 정제를 제조하기 위해 활용될 수 있다.For example, the food composition for diet according to the present invention comprises 35 to 45% by weight of chicory dietary fiber, 15 to 25% by weight of L-tryptophan, 35 to 40% by weight of crystalline cellulose, 1 to 5% by weight of carboxymethylcellulose 1 to 5% by weight of silicon dioxide, 0.1 to 2% by weight of magnesium stearate, 0.1 to 1% by weight of hydroxypropyl methylcellulose, 0.1 to 1% by weight of glycerol fatty acid ester and 0.1 to 1% Can be utilized to prepare dietary tablets, including% w / w alcohol.
바람직하게는, 상기 치커리 식이섬유 37 내지 40 중량%, 18 내지 20 중량%의 L-트립토판, 35 내지 37중량%의 결정 셀룰로오스, 2 내지 4 중량%의 카르복시메틸 셀룰로오즈(CMC-Ca salt), 1.5 내지 2 중량%의 이산화규소, 0.5 내지 1.5 중량%의 스테아린산 마그네슘, 0.3 내지 0.8 중량%의 하이드록시프로필 메틸 셀룰로오스, 0.3 내지 0.8 중량%의 글리세린 지방산에스테르 및 0.3 내지 0.8 중량%의 주정을 포함하도록 구성할 수 있다.Preferably, the chicory dietary fiber comprises 37 to 40 wt%, 18 to 20 wt% of L-tryptophan, 35 to 37 wt% of crystalline cellulose, 2 to 4 wt% of carboxymethyl cellulose (CMC-Ca salt) To about 2% by weight of silicon dioxide, from 0.5 to 1.5% by weight of magnesium stearate, from 0.3 to 0.8% by weight of hydroxypropyl methylcellulose, from 0.3 to 0.8% by weight of glycerin fatty acid esters and from 0.3 to 0.8% can do.
나아가, 본 발명에 따른 다이어트용 식품 조성물은 비타민 B1, 비타민 B2, 비타민 B6, 비타민 B12 등과 같은 비타민 B군을 추가로 포함하도록 구성하여 L-트립토판의 장기간 섭취 또는 과량 섭취로 인해 야기될 수 있는 기능 저하를 방지하도록 구성할 수 있으며, 바람직하게는, 600 내지 750 mg의 총중량을 갖는 정제의 경우, 결정 셀룰로오스 대신 50 내지 200 mg의 비타민 B2(riboflavin)를 혼합하도록 구성할 수 있다.Further, the food composition for diet according to the present invention may further comprise a vitamin B group such as vitamin B1, vitamin B2, vitamin B6, and vitamin B12, and may further comprise a function that can be caused by prolonged intake or overdose of L-tryptophan And preferably, in the case of tablets having a total weight of 600 to 750 mg, 50 to 200 mg of vitamin B2 (riboflavin) may be mixed instead of crystalline cellulose.
상기와 같은 본 발명에 따른 다이어트용 식품 조성물은, L-트립토판과 치커리 식이섬유를 유효성분으로 포함하여, 심리적 및 육체적 포만감 증진을 통한 식욕조절과 배변 촉진 효능의 시너지 효과를 유도하여 우수한 비만 개선 효능을 가지며, 특히, 상기 조성물로 제조된 정제는 섭취가 간편하여 L-트립토판이 갖는 섭취의 불편함을 개선하여 다이어트를 위한 용도로 손쉽게 활용이 가능하다.The food composition for diet according to the present invention as described above contains L-tryptophan and chicory dietary fiber as an active ingredient to induce a synergistic effect of controlling appetite and promoting bowel movement by enhancing psychological and physical filling feeling, In particular, the tablets made from the above composition are easy to ingest and can be easily used for dieting by improving the inconvenience of intake of L-tryptophan.
한편, 본 발명은, (a) 치커리 식이섬유, L-트립토판, 결정셀룰로오스, 칼슘 카르복시메틸 셀룰로오즈(CMC-Ca salt), 이산화규소 및 주정을 포함하는 혼합물을 과립화하여 과립을 제조하는 단계; (b) 상기 과립 및 활택제를 혼합하고 타정하여 나정(naked tablet)을 제조하는 단계; 및 (c) 상기 나정의 표면에 코팅제를 코팅하여 정제(tablet)를 제조하는 단계를 포함하는 다이어트용 정제의 제조방법을 제공한다.On the other hand, the present invention provides a method for producing granules comprising the steps of: (a) granulating a mixture containing chicory dietary fiber, L-tryptophan, crystalline cellulose, CMC-Ca salt, silicon dioxide and alcohol to prepare granules; (b) mixing and granulating the granules and the glidant to form an naked tablet; And (c) coating the surface of the tablet with a coating agent to prepare tablets.
상기 단계 (a)는, 치커리 식이섬유, L-트립토판, 결정셀룰로오스, 칼슘 카르복시메틸 셀룰로오즈(CMC-Ca salt), 이산화규소 및 주정을 포함하는 혼합물을 과립화하여 과립을 제조하는 단계이다.The step (a) is a step of granulating a mixture containing chicory dietary fiber, L-tryptophan, crystalline cellulose, CMC-Ca salt, silicon dioxide and alcohol to prepare granules.
본 단계에서는, 치커리 식이섬유를 에탄올 등과 같은 주정과 혼합하고 균일하게 분산되도록 충분한 시간 동안 교반한 다음, L-트립토판, 결정셀룰로오스, 칼슘 카르복시메틸 셀룰로오즈, 이산화규소를 혼합하여 혼합물을 제조할 수 있으며, 제조한 혼합물을 유동형 과립기, 분무형 과립기 등과 같은 과립성형기에 투입하고 혼합물을 성형한 후 건조하여 과립을 제조할 수 있으며, 평균직경이 1 내지 5 mm가 되도록 성형하여 과립을 제조할 수 있다.In this step, the mixture can be prepared by mixing L-tryptophan, crystalline cellulose, calcium carboxymethyl cellulose and silicon dioxide after mixing the chicory dietary fiber with the alcohol such as ethanol and stirring for a sufficient time to disperse uniformly, The thus-prepared mixture is introduced into a granulating machine such as a flow type granulator, spray granulator, etc., and the mixture is molded and dried to produce granules. The granules can be manufactured by shaping the granules so as to have an average diameter of 1 to 5 mm .
또한, 본 단계에서는 상기 혼합물을 제조할 시, 상기 혼합물에 비타민 B군을 추가적으로 혼합하도록 구성할 수 있다.In this step, the vitamin B group may be further added to the mixture when the mixture is prepared.
상기 단계 (b)는, 상기 과립 및 활택제를 혼합하고 타정하여 나정(naked tablet)을 제조하는 단계로서, 제조한 과립 및 활택제 혼합물을 정제 제조를 위해 통상적으로 사용되는 제환기, 펠렛 타정기 등에 투입한 후 압착하여 나정을 제조할 수 있으며, 이와 같은 활택제로는 스테아린산마그네슘을 사용할 수 있다.The step (b) is a step of mixing and granulating the granules and a lubricant to prepare an naked tablet. The granules and the lubricant mixture thus prepared are mixed in a ventilator, a pelletizer, etc., And the mixture can be pressed to form a kneaded product. Magnesium stearate may be used as such a lubricant.
또한, 본 단계에서는 제조된 나정의 평균 중량이 600 내지 750 mg이 되도록 나정을 제조하는 것이 바람직하다.Also, in this step, it is preferable to manufacture the nunner so that the average weight of the manufactured nuns is 600 to 750 mg.
상기 단계 (c)는, 상기 나정의 표면에 코팅제를 코팅하여 정제(tablet)를 제조하는 단계로서, 하이드록시프로필 메틸 셀룰로오스 및 글리세린 지방산에스테르를 에탄올 등과 같은 주정을 용매로 사용해 혼합하여 코팅용액을 제조하고, 제조한 코팅용액을 나정의 표면에 코팅한 후 하이드록시프로필 메틸 셀룰로오스 및 글리세린 지방산에스테르를 가교시키고 건조하여 나정의 표면에 코팅제가 코팅된 형태의 정제를 제조할 수 있다. 이와 같은 코팅 단계는 필요에 따라 수회 반복수행하도록 구성할 수 있다.The step (c) is a step of preparing a tablet by coating a coating agent on the surface of the tablet, wherein hydroxypropyl methylcellulose and glycerin fatty acid ester are mixed using a solvent such as ethanol as a solvent to prepare a coating solution The coating solution thus prepared is coated on the surface of the tablet, and hydroxypropyl methylcellulose and glycerin fatty acid ester are cross-linked and dried to prepare tablets in the form of a coating agent coated on the surface of the tablet. Such a coating step can be configured to be repeated several times as required.
또한, 본 단계에서는 상기와 같이 코팅제를 코팅하여 제조한 정제를 통상적인 다양한 포장 방법을 이용하여 포장하는 단계를 추가로 포함하도록 구성할 수 있으며, 이와 같은 방법으로 포장한 정제를 제품화하여 시판할 수 있다.In this step, the tablets prepared by coating the coating agent as described above may be further packed by using various conventional packing methods. The packaged tablets may be commercialized and marketed have.
상기한 바와 같은 본 발명에 따른 제조방법에 따르면, L-트립토판과 치커리 식이섬유를 포함하는 혼합물을 과립화하고, 활택제를 혼합하여 나정을 제조한 후, 나정에 코팅층을 형성시켜 정제를 제조함에 따라, 목넘김 부담을 최소화하고, 정제의 방출을 제어할 수 있어 다이어트를 위한 용도로 손쉽게 활용이 가능한 다이어트용 정제를 제조할 수 있다.According to the manufacturing method of the present invention as described above, a mixture containing L-tryptophan and chicory dietary fiber is granulated, a lubricant is mixed by mixing the lubricant, and a coating layer is formed on the flange to prepare tablets Accordingly, it is possible to minimize the burden of necking and to control the release of the tablet, thereby making it possible to produce a tablet for diet that can be easily used for a diet.
본 명세서에서 설명되는 실시예와 첨부된 도면은 본 발명에 포함되는 기술적 사상의 일부를 예시적으로 설명하는 것에 불과하다. 따라서, 본 명세서에 개시된 실시예는 본 발명의 기술적 사상을 한정하기 위한 것이 아니라 설명하기 위한 것이므로, 이러한 실시예에 의하여 본 발명의 기술 사상의 범위가 한정되는 것은 아님은 자명하다. 본 발명의 명세서 및 도면에 포함된 기술적 사상의 범위 내에서 당업자가 용이하게 유추할 수 있는 변형예와 구체적인 실시예는 모두 본 발명의 권리범위에 포함되는 것으로 해석되어야 할 것이다.The embodiments and the accompanying drawings described in the present specification are merely illustrative of some of the technical ideas included in the present invention. Therefore, it is to be understood that the embodiments disclosed herein are not for purposes of limiting the technical idea of the present invention, but rather are not intended to limit the scope of the technical idea of the present invention. It will be understood by those of ordinary skill in the art that various changes in form and details may be made therein without departing from the spirit and scope of the invention as defined by the appended claims.
이하, 본 발명을 실시예를 들어 더욱 상세히 설명하도록 한다.Hereinafter, the present invention will be described in more detail with reference to examples.
제시된 실시예는 본 발명의 구체적인 예시일 뿐이며, 본 발명의 범위를 제한하기 위한 것은 아니다.The embodiments presented are only a concrete example of the present invention and are not intended to limit the scope of the present invention.
<실시예><Examples>
하기 표 1에 나타낸 바와 같은 조성 및 배합비율을 갖는 다이어트용 정제를 제조하였다. Tablets for diet having compositions and mixing ratios as shown in Table 1 below were prepared.
이를 위해, 먼저, 치커리 식이섬유 및 L-트립토판을 정제(tablet) 주원료로 하고, 결정셀룰로오스, CMC칼슘, 이산화규소를 정제 부원료로 하여 이를 균질하게 혼합한 혼합물을 과립성형기에 넣고 성형하여 과립을 제조하였다. 제조한 과립에 활택제로 스테아린산마그네슘을 첨가한 후 혼합하여 혼합물을 제조하고, 제조한 혼합물을 타정기에 투입하여 나정을 제조하였다.To this end, a mixture of homogeneously mixed crystalline cellulose, CMC calcium, and silicon dioxide as a refining auxiliary material is used as a main raw material of chicory dietary fiber and L-tryptophan as a tablet, and the mixture is molded into a granule molding machine Respectively. Magnesium stearate was added as a lubricant to the prepared granules, followed by mixing to prepare a mixture. The mixture thus prepared was put into a tablet machine to prepare a tablet.
다음, 하이드록시프로필메틸셀룰로오스(HPMC), 글리세린지방산에스테르 및 주정을 혼합하여 코팅용액을 제조하였고, 제조한 코팅용액을 나정에 분무 코팅하였으며, 코팅용액이 코팅된 정제를 건조하고, 진공포장하여 정제를 제조하였다.Next, a coating solution was prepared by mixing hydroxypropylmethylcellulose (HPMC), glycerin fatty acid ester, and alcohol, spray-coating the prepared coating solution on the nail, drying the tablet coated with the coating solution, .
<비교예 1>≪ Comparative Example 1 &
치커리 식이섬유 대신 글루코만난을 동일 배합비율 및 투입량으로 배합하는 것을 제외하고는 실시예와 동일한 방법으로 정제를 제조하였다.Tablets were prepared in the same manner as in Example except that glucomannan was used instead of Chicory dietary fiber at the same mixing ratio and dosage.
<비교예 2>≪ Comparative Example 2 &
L-트립토판 대신 L-카르니틴을 동일 배합비율 및 투입량으로 배합하는 것을 제외하고는 실시예와 동일한 방법으로 정제를 제조하였다.Purification was carried out in the same manner as in Example except that L-carnitine was used instead of L-tryptophan in the same mixing ratio and dose.
<비교예 3>≪ Comparative Example 3 &
L-트립토판을 첨가하지 않고 치커리 식이섬유 375 mg을 혼합하는 것을 제외하고는 실시예와 동일한 방법으로 정제를 제조하였다. Tablets were prepared in the same manner as in Example except that 375 mg of chicory dietary fiber was added without adding L-tryptophan.
<비교예 4>≪ Comparative Example 4 &
L-트립토판을 첨가하지 않고 글루코만난 375 mg을 혼합하는 것을 제외하고는 실시예와 동일한 방법으로 정제를 제조하였다. Purification was carried out in the same manner as in Example except that 375 mg of glucomannan was added without adding L-tryptophan.
<실험예 1> 포만감 분석≪ Experimental Example 1 >
20세 이상 남성 30명, 여성 20명로 구성된 총 35명의 피실험자를 대상으로 제조한 정제가 갖는 포만감 부여 정도를 분석하였다. 남성 피실험자의 평균 체중은 74.8 kg이었고, 여성 피실험자의 평균 체중은 53.7 kg이었으며, 피실험자들은 수면 이후 음식물 섭취를 제한하여 공복의 상태에서 섭취 전 포만감을 0으로 산정하고 포만감 정도를 분석하였고, 실시예 및 비교예 1 내지 4에 따른 방법으로 제조한 정제를 물과 함께 조식 대신 섭취하도록 하고, 섭취 후 매 1시간 간격으로 느껴지는 포만감을 0 ± 20으로 나뉘어진 설문지에 기록하여 평균값을 산출하여 포만감 부여 정도를 분석하였고, 그 결과를 하기의 표 2에 나타내었다.A total of 35 subjects consisting of 30 males and 20 females over 20 years of age were analyzed for their satiety levels. The mean body weight of male subjects was 74.8 kg, the average weight of female subjects was 53.7 kg, and subjects were restricting food intake after sleeping, so that the satiety before eating was calculated as 0 and the satiety degree was analyzed. The tablets prepared by the methods of Comparative Examples 1 to 4 were taken in the place of breakfast with water and the fullness felt at intervals of 1 hour after ingestion was recorded in a questionnaire divided into 0 ± 20 and the average value was calculated to give a satisfactory degree of fullness And the results are shown in Table 2 below.
표 2에 나타난 바와 같이, 실시예의 정제를 섭취한 군의 포만감이 가장 높은 것으로 확인되었으며, 섭취후 1시간이 경과한 시점에 포만감이 최고조에 이르고, 시간이 경과함에 따라 포만감이 지속적으로 감소된다는 사실을 확인할 수 있었다.As shown in Table 2, it was confirmed that the fullness of the group ingesting the tablets of the Example was the highest, and the satiety feeling reached its peak at 1 hour after ingestion, and the satiety was continuously decreased with time .
또한, L-트립토판 및 치커리 식이섬유를 동시에 포함하는 실시예의 정제가 가장 높은 포만감 부여 능력을 갖는 것으로 확인되었으며, 치커리 식이섬유 대신 글루코만난을 배합한 정제의 경우 식이섬유를 과량 포함함에 따라 포만감을 부여하는 역할을 할 수 있으나, 이눌린의 함량이 낮아 실시예에 비해 포만감 유도효과가 다소 떨어진다고 예측할 수 있었으며, 이와 같은 사실을 통해서, 실시예에 따른 정제가 L-트립토판 및 치커리 식이섬유에 의한 심리적 및 육체적 포만감 증진을 통한 시너지 효과가 유도되어 장시간 동안 식욕 조절이 가능한 것으로 판단되었다.In addition, it has been confirmed that the tablets of the Examples simultaneously containing L-tryptophan and chicory dietary fiber have the highest ability to impart satiety, and in the case of tablets containing glucomannan instead of chicory dietary fiber, But the inulin content was low, so it was predicted that the satiety inducing effect was somewhat lowered compared with the examples. Through these facts, it can be concluded that the tablets according to the examples have a psychological and physical satisfaction with L-tryptophan and chicory dietary fiber It was judged that appetite control was possible for a long time by inducing synergy effect through promotion.
<실험예 2> 체중감량 효과 분석<Experimental Example 2> Analysis of weight loss effect
실시예 및 비교예 1 내지 4에 따른 방법으로 제조한 정제가 갖는 체중감량 효과를 분석하기 위해서, 비만이 유도된 레트(rat)를 이용해 체중 증가량을 분석하는 방법을 이용하였다.In order to analyze the weight loss effects of tablets prepared by the method according to Examples and Comparative Examples 1 to 4, a method of analyzing weight gain using a rat induced by obesity was used.
먼저, 8주령 Sparague-Dawley 종 수컷 레트(평균 체중 210 ± 10 g) 30마리에 고지방식이를 4주 동안 급여하여 비만을 유발하였다. 비만이 유발된 30마리의 쥐를 5마리씩 6개의 군으로 나누어 실시예 및 비교예 1 내지 4의 정제 각각 0.1 g을 식이급여 5분 전에 먼저 급여한 후 고지방식이 4.9 g을 급여하였으며, 4주 동안 급여하여 레트의 1주일별 체중 증가량을 분석하였으며, 그 결과를 하기의 표 3에 나타내었다(단, 1개 군은 고지방식이를 급여한 대조군의 군임).First, 30 weeks old Sparague-Dawley male rats (mean weight 210 ± 10 g) were fed with high fat diet for 4 weeks to induce obesity. Thirty rats in which obesity was induced were divided into 6 groups of 5 rats and each 0.1 g of each of the tablets of Examples and Comparative Examples 1 to 4 was fed 5 minutes before the diet and 4.9 g by the high fat diet. . The results are shown in Table 3 below (one group is a control group fed with high fat diet).
표 3에 나타난 바와 같이, 대조군의 체중증가량은 131%인 것으로 확인된 반면에 실시예 및 비교예 1 내지 4에 따른 방법으로 제조한 정제를 투여한 레트는 정제를 급여한 이후에는 모두 체중이 감소된다는 사실을 확인할 수 있었고, 제조한 정제를 급여한 레트의 경우 고지방식이를 모두 섭취하지 않는다는 사실을 확인할 수 있었다. As shown in Table 3, while the weight gain of the control group was confirmed to be 131%, the rats administered the tablets prepared by the method according to the examples and comparative examples 1 to 4, And it was confirmed that the recipients fed the prepared tablets did not take all of the high fat diet.
특히, 실시예에 따른 정제를 급여한 레트 군에서는 식이 섭취량이 가장 낮다는 사실을 확인할 수 있었으며, 실시예에 따른 정제를 4주 동안 선급여하여 체중 증가율이 -47.9%로 현저히 저감되는 것을 확인할 수 있었으며, 4주 동안 선급여할 시 레트의 식이 섭취량이 가장 낮다는 사실을 확인할 수 있어, 비만 개선 효과가 L-트립토판 및 치커리 식이섬유의 시너지 효과로 인해 포만감이 크게 증가되어 비만 개선 효과가 가장 우수하다는 사실을 확인할 수 있었다.In particular, it was confirmed that the dietary intake was the lowest in the group fed the tablets according to the examples, and it was confirmed that the body weight gain rate was significantly reduced to -47.9% by feeding the tablets according to the examples for 4 weeks And it was confirmed that the dietary intake of cetyltreate for 4 weeks was the lowest, and the obesity improvement effect was greatly improved by the synergy effect of L-tryptophan and chicory dietary fiber, and the obesity improvement effect was the most excellent I was able to confirm the fact.
상기와 같은 결과를 통해서, 본 발명에 따른 다이어트용 식품 조성물이 장시간 동안 포만감을 형성시켜줌은 물론 비만을 개선하는 효과가 있다는 사실을 확인할 수 있어 다이어트를 위한 용도로 손쉽게 사용이 가능할 것으로 판단되었다.As a result, it can be confirmed that the food composition for diet according to the present invention has the effect of improving the obesity as well as the satiety feeling for a long time, so that it can be easily used for dieting.
Claims (8)
결정 셀룰로오스, 칼슘 카르복시메틸 셀룰로오즈(CMC-Ca salt), 스테아린산 마그네슘, 하이드록시프로필 메틸 셀룰로오스, 글리세린 지방산에스테르 및 주정을 추가로 포함하는 것을 특징으로 하는 다이어트용 식품 조성물.The method according to claim 1,
Wherein the composition further comprises crystalline cellulose, calcium carboxymethyl cellulose (CMC-Ca salt), magnesium stearate, hydroxypropylmethyl cellulose, glycerin fatty acid ester and alcohol.
35 내지 45 중량%의 치커리 식이섬유, 15 내지 25 중량%의 L-트립토판, 35 내지 40중량%의 결정 셀룰로오스, 1 내지 5 중량%의 카르복시메틸 셀룰로오즈(CMC-Ca salt), 1 내지 5 중량%의 이산화규소, 0.1 내지 2 중량%의 스테아린산 마그네슘, 0.1 내지 1 중량%의 하이드록시프로필 메틸 셀룰로오스, 0.1 내지 1 중량%의 글리세린 지방산에스테르 및 0.1 내지 1 중량%의 주정을 포함하는 것을 특징으로 하는 다이어트용 식품 조성물.3. The method of claim 2,
35 to 40% by weight of crystalline cellulose, 1 to 5% by weight of carboxymethyl cellulose (CMC-Ca salt), 1 to 5% by weight of lactose, 35 to 45% by weight of chicory fiber, 15 to 25% By weight of silicon dioxide, 0.1 to 2% by weight of magnesium stearate, 0.1 to 1% by weight of hydroxypropyl methylcellulose, 0.1 to 1% by weight of glycerin fatty acid ester and 0.1 to 1% ≪ / RTI >
상기 다이어트용 식품 조성물은 정제(tablet) 제형을 갖는 것을 특징으로 하는 다이어트용 식품 조성물.The method of claim 3,
Wherein the food composition for diet has a tablet formulation.
상기 정제는 100 내지 150 mg의 L-트립토판 및 200 내지 300 mg의 치커리 식이섬유를 포함하는 것을 특징으로 하는 다이어트용 식품 조성물.5. The method of claim 4,
Wherein the tablet comprises 100 to 150 mg of L-tryptophan and 200 to 300 mg of chicory dietary fiber.
(b) 상기 과립 및 활택제를 혼합하고 타정하여 나정(naked tablet)을 제조하는 단계; 및
(c) 상기 나정의 표면에 코팅제를 코팅하여 정제(tablet)를 제조하는 단계를 포함하는 다이어트용 정제의 제조방법.(a) granulating a mixture comprising chicory dietary fiber, L-tryptophan, crystalline cellulose, CMC-Ca salt, silicon dioxide and alcohol to produce granules;
(b) mixing and granulating the granules and the glidant to form an naked tablet; And
(c) coating the surface of the tablet with a coating agent to prepare a tablet.
상기 활택제는 스테아린산마그네슘을 포함하는 것을 특징으로 하는 다이어트용 정제의 제조방법.The method according to claim 6,
Wherein the lubricant comprises magnesium stearate.
상기 코팅제는 하이드록시프로필 메틸 셀룰로오스, 글리세린 지방산에스테르 및 주정을 포함하는 것을 특징으로 하는 다이어트용 정제의 제조방법.The method according to claim 6,
Wherein the coating agent comprises hydroxypropylmethylcellulose, a glycerin fatty acid ester, and a meal.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020170101099A KR20190016755A (en) | 2017-08-09 | 2017-08-09 | Diet-food composition for inducing satiation comprising L-tryptophan and dietary fiber of chicory and method for preparing diet tablet using the same |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020170101099A KR20190016755A (en) | 2017-08-09 | 2017-08-09 | Diet-food composition for inducing satiation comprising L-tryptophan and dietary fiber of chicory and method for preparing diet tablet using the same |
Publications (1)
Publication Number | Publication Date |
---|---|
KR20190016755A true KR20190016755A (en) | 2019-02-19 |
Family
ID=65528836
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020170101099A KR20190016755A (en) | 2017-08-09 | 2017-08-09 | Diet-food composition for inducing satiation comprising L-tryptophan and dietary fiber of chicory and method for preparing diet tablet using the same |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR20190016755A (en) |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20130030049A (en) | 2011-09-16 | 2013-03-26 | 이현재 | The health food composition for regulating weight and increasing the satiety |
KR101341475B1 (en) | 2013-05-16 | 2013-12-13 | 주식회사 소울네이처푸드 | Healthy diet food composite without adverse effect and manufacturing method thereof |
KR20170069464A (en) | 2015-12-11 | 2017-06-21 | (주) 머니키 | Health care food of composition comprising the extract material in garcinia cambogia |
-
2017
- 2017-08-09 KR KR1020170101099A patent/KR20190016755A/en unknown
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20130030049A (en) | 2011-09-16 | 2013-03-26 | 이현재 | The health food composition for regulating weight and increasing the satiety |
KR101341475B1 (en) | 2013-05-16 | 2013-12-13 | 주식회사 소울네이처푸드 | Healthy diet food composite without adverse effect and manufacturing method thereof |
KR20170069464A (en) | 2015-12-11 | 2017-06-21 | (주) 머니키 | Health care food of composition comprising the extract material in garcinia cambogia |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2509477C1 (en) | New sweeteners compositions | |
JP6271571B2 (en) | Composition for maintaining intestinal microbiota equilibrium, process for producing the composition, and use of the composition | |
JP5121308B2 (en) | Composition for preventing, improving or treating metabolic syndrome | |
JP2002508772A (en) | Health supplement | |
JPH0773480B2 (en) | Amino acid based nutrition pellets | |
KR20070112811A (en) | Amino acid composition for improving glucose tolerance | |
WO2010038238A2 (en) | Dietary fiber compositions | |
JP2016053062A (en) | Use of saffron and/or safranal and/or picrocrocin and/or crocin and/or derivatives thereof for treatment of obesity | |
CN106723087A (en) | A kind of tablet containing kelp dietary fiber and preparation method thereof | |
AU2016253140B2 (en) | Plant extracts for the treatment of excess weight and obesity | |
US8323682B2 (en) | Appetite suppressant product and method | |
JP6861169B2 (en) | Compositions for Weight Loss Containing Beverages and Beads | |
Bortolotti et al. | Effect of a balanced mixture of dietary fibers on gastric emptying, intestinal transit and body weight | |
JP4974473B2 (en) | Oral composition for promoting defecation containing patchouli oil and dietary fiber | |
JP2004194635A (en) | Diet food | |
JP2003113089A (en) | Chitosan-containing formulation having action to inhibit lipid accumulation and reduce cholesterol and food and drink | |
KR20190016755A (en) | Diet-food composition for inducing satiation comprising L-tryptophan and dietary fiber of chicory and method for preparing diet tablet using the same | |
JP3807464B2 (en) | Anti-obesity agent | |
JP2009209088A (en) | Muscle-enhancing agent containing asperuloside or its analog | |
JP4645791B2 (en) | Composition for preventing or improving hyperfree fatty acidemia | |
JP2001048794A (en) | Health food and medicinal composition which contain mixture of powder originated from leaf of mulberry and powder originated from oyster and is used for treating niddm | |
TWI784169B (en) | Prevention or improvement agent for nocturnal frequent urination | |
JP2018087172A (en) | Lipid burning promoter | |
JP2003261445A (en) | Agent for suppressing neutral fat level in blood | |
JP4465963B2 (en) | Composition for preventing or improving hyperlipidemia |